Mostrando 321 - 340 Resultados de 1,900 Para Buscar '"AstraZeneca"', tiempo de consulta: 0.75s Limitar resultados
  1. 321
    por Putter, Jeffrey S.
    Publicado 2021
    “…These include the Pfizer and Moderna first mRNA vaccines under FDA purview and the Oxford/AstraZeneca simian adenovirus-vectored vaccine (under UK-MHPRA guidance), all produced in record time, being safe and effective. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 322
    “…Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 323
    “…Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value < 0.0001 of both. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  4. 324
    “…Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  5. 325
  6. 326
    “…No exam questions will be disclosed ., Other Financial or Material Support David Tribble, M.D., DrPH, Astra Zeneca (Other Financial or Material Support, HJF, in support of USU IDCRP, funded under a CRADA to augment the conduct of an unrelated Phase III COVID-19 vaccine trial sponsored by AstraZeneca as part of USG response (unrelated work)) Simon Pollett, MBBS, Astra Zeneca (Other Financial or Material Support, HJF, in support of USU IDCRP, funded under a CRADA to augment the conduct of an unrelated Phase III COVID-19 vaccine trial sponsored by AstraZeneca as part of USG response (unrelated work))…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 327
    “…The first and second doses of COVID-19 vaccinations (Pfizer BioNTech BNT162b2 or Oxford AstraZeneca ChAdOx1 nCoV-19) were administered to this patient cohort since January 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 328
    “…In all priority age groups and all regions, a higher percentage of complete CoronaVac vaccination schedules were observed compared with AstraZeneca. The temporal analysis identified high VR clusters of CoronaVac first and second dose in the early weeks, except for the EP; of AstraZeneca first dose, only for HW in the early weeks, and for EP and I/Q in the final weeks; of AstraZeneca second dose for all priority groups in the final weeks. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 329
    “…METHODS: Using a retrospective cohort study design, 6600 subjects aged 18 years or older who had received two doses of any of the three COVID-19 vaccines (Sinopharm, AstraZeneca, and Sputnik V) were selected using a random sampling method between March and August 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 330
    “…On the other hand, the IgG levels were significantly higher in CD patients who received the Pfizer relative to the AstraZeneca vaccine (58.3 ±45.5 vs. 13.0 ±23.6, p = 0.03). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 331
    “…Ison, MD MS, Adagio: Advisor/Consultant|Adamis: Advisor/Consultant|Adamis: Board Member|ADMA Biologics: Advisor/Consultant|AlloVir: Advisor/Consultant|AlloVir: Board Member|Atea: Advisor/Consultant|Cidara: Advisor/Consultant|CSL Behring: Board Member|Genentech/Roche: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Board Member|Merck: Board Member|NIH: Board Member|Romark: Advisor/Consultant|Seqiris: Board Member|Shionogi: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Board Member|Talaris: Advisor/Consultant|Talaris: Board Member|UpToDate: Stocks/Bonds|Viracor Eurofins: Advisor/Consultant Alberto Papi, MD, Agenzia Italiana del farmaco (AIFA): Grant/Research Support|AstraZeneca: Advisor/Consultant|AstraZeneca: Board Member|AstraZeneca: Grant/Research Support|AstraZeneca: Honoraria|Avillon: Advisor/Consultant|Avillon: Honoraria|Chiesi Farmaceutici: Advisor/Consultant|Chiesi Farmaceutici: Board Member|Chiesi Farmaceutici: Grant/Research Support|Chiesi Farmaceutici: Honoraria|EdmondPharma: Honoraria|Elpen Pharmaceuticals: Advisor/Consultant|Elpen Pharmaceuticals: Honoraria|GSK: Advisor/Consultant|GSK: Board Member|GSK: Grant/Research Support|MENARINI: Honoraria|Mundipharma: Honoraria|Novartis: Advisor/Consultant|Novartis: Honoraria|Qivia: Honoraria|Sanofi: Advisor/Consultant|Sanofi: Board Member|Sanofi: Grant/Research Support|Sanofi: Honoraria|Zambon: Honoraria Joanne M. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  12. 332
    por Kanavos, Panos, Angelis, Aris
    Publicado 2014
    “…The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public agenda. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  13. 333
    “…There have been rare reports of thrombosis after vaccination with the AstraZeneca vaccine. We present three cases of vaccine-induced thrombotic thrombocytopenia (VITT) in one UK district general hospital following administration of this vaccine. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 334
    “…To the best of our knowledge, there have been no reports of PR-like eruptions following inoculation with Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine. Here, we described a case of PR-like eruption that developed 14 days after Oxford/AstraZeneca vaccination in a 52-year-old Thai woman with glioblastoma. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 335
    “…We present a case of VITT-associated sinus thrombosis secondary to the AstraZeneca (ChAdOx1 nCov-19) vaccine, which was complicated by a large intracerebral haemorrhage.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 336
    “…One patient developed the first symptoms three days after the second vaccination (first vaccination ChadOx-1, Astra Zeneca; second vaccination CX-024414, Moderna); in the second patient, symptoms started 28 days after the first vaccination (ChadOx-1, Astra Zeneca). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  17. 337
    “…Since he recently had the COVID-19 AstraZeneca vaccine, it was postulated as the most likely cause of the symptoms. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 338
    “…The mean severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike receptor-binding domain immunoglobulin G antibody level in the ninth month was the highest among those who had received the Pfizer vaccine (6.7930), followed by AstraZeneca (2.8492), and Sinopharm (0.3060). In the 12th month, all 82 participants received Pfizer as a booster dose, and the highest mean SARS-CoV-2 anti-spike receptor-binding domain immunoglobulin G antibody in the 12th month belonged to those whose second dose was Pfizer (46.8835), followed by AstraZeneca (36.4635), and Sinopharm (21.7815). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 339
    “…The comparison of results demonstrated that AstraZeneca vaccine is a superior candidate vaccine for COVID-19 vaccination out of the three. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 340
    “…Aim of the work: We aim to evaluate the effectiveness of Pfizer and AstraZeneca vaccines in preventing breakthrough infection, as well as to determine the possible risk factors and outcomes of post-vaccination infection. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS